Funding Details
- Awarder
- Inbox
- Date Award
- January 13, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- The company is preparing to begin a Phase 2 trial investigating WIN378 in severe asthma, with initial clinical readouts expected in 2026.
- Founders
- Luca Santarelli, MD
- Company Description
- Windward Bio develops monoclonal antibodies for advanced immunological diseases.
- Market
- Clinical-stage drug development for immunological diseases
- Location
-
Switzerland
- Coinvestors
- OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, Pivotal bioVenture Partners
Links